Atara Biotherapeutics (NASDAQ:ATRA) and Its Competitors Head to Head Survey

Atara Biotherapeutics (NASDAQ: ATRA) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Atara Biotherapeutics to similar companies based on the strength of its dividends, earnings, analyst recommendations, risk, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares Atara Biotherapeutics and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Atara Biotherapeutics N/A -$79.04 million -8.14
Atara Biotherapeutics Competitors $290.27 million $35.99 million 56.60

Atara Biotherapeutics’ peers have higher revenue and earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Atara Biotherapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics’ peers have a beta of 2.35, suggesting that their average stock price is 135% more volatile than the S&P 500.


This table compares Atara Biotherapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atara Biotherapeutics N/A -44.82% -41.82%
Atara Biotherapeutics Competitors -5,443.85% -164.39% -36.43%

Analyst Ratings

This is a summary of current recommendations for Atara Biotherapeutics and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atara Biotherapeutics 0 2 3 0 2.60
Atara Biotherapeutics Competitors 1134 3426 11925 240 2.67

Atara Biotherapeutics currently has a consensus target price of $28.75, suggesting a potential upside of 1.77%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.80%. Given Atara Biotherapeutics’ peers stronger consensus rating and higher possible upside, analysts plainly believe Atara Biotherapeutics has less favorable growth aspects than its peers.

Insider & Institutional Ownership

85.6% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.2% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


Atara Biotherapeutics peers beat Atara Biotherapeutics on 10 of the 13 factors compared.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company’s product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company’s T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with's FREE daily email newsletter.

Leave a Reply